Abveris and Abilita Bio Announce Collaboration to Develop Therapeutics for Challenging Membrane Protein Targets
– The research collaboration will leverage synergies between...
The limiting factor for most in vivo discovery platforms is the diversity of the host animal's immune response. Abveris' discovery platform is propelled by proprietary, genetically engineered hyperimmune mouse strains, the DiversimAbTM family. Due to autoimmune features, our mouse strains offer a competitive advantage in the generation of murine antibodies against epitopes and proteins with high homology to a mouse ortholog.
DiversimAbTM mice provide an advantage in nearly any custom antibody discovery application due to the increased epitopic diversity of the mAbs resulting from the mice.
Utilizing the DiversimAb technology, Abveris has developed hyperimmune mice of two strain backgrounds (DiversimAbTM and DivergimAbTM) with different MHC haplotypes to produce additional, complementary diversity in discovery campaigns.
As a benefit of enhanced antibody diversities, DiversimAbTM platform readily enables the discovery of species cross-reactive antibodies, including human, cyno, and mouse cross-reactive antibodies.
Our auto-immune, hyperimmune model enables the delivery of panels of mAbs against targets (such as cell surface receptors), and epitopes on those targets, that do not elicit an immune response in natural mice. We've delivered mAbs against 100% mouse proteins out of DiversimAbTM mice.
Comparing Titers of DiversimAbTM and Balb/c Mice with Targets of Increasing Sequence Homology
Abveris uses custom immunization protocols optimized for DiversimAbTM for multi-spanners (such as GPCR and ion channels), high homology targets, and other poor immunogens. We have developed rapid immunization strategies to elicit robust immune responses without sacrifices in antibody affinity or quality, leading to the identification of diverse panels of antibodies in weeks, not months.
Our proprietary adjuvant suite is stacked with custom formulations that give us an edge across targets and in-vivo models. Many options available, connect with our team to learn more.
Abveris offers royalty-free, flexible business models, including fee-for-service and equity-for-service structures, for the access to the DiversimAbTM platform.